CN |CAS  
 
  Home | Links | Site map
 
Home About Us News Organization Research Faculty Publication Education&Training Contact
  Research
Location: Home > Research
 
 
Research
Target
Discovery
Development
Translation
 
Dr Qiang Yu’s group of the SIMM Institute reported new discoveries in “Cancer Research”
Update time: 2009-09-21
Close
Text Size: A A A
Print

  Dr Qiang Yu’s group of the SIMM Institute reported in the recent issue of “Cancer Research” the discovery of a novel mechanism of a Traditional Chinese Medicine in treating cancer.  The traditional Chinese herb medicine Euphorbia fischeriana Steud has been widely used in China for treating various cancers.  Several compounds in the medicinal herb have been reported to have anti-tumor effects.  The mechanisms of these compounds in inhibiting tumor growth, however, have not been fully understood.  Dr. Ying Wang, a graduate student from Dr Yu’s group, identified 17-hydroxy-jolkinolide B (HJB) from the herb as a novel inhibitor of the JAK family kinases. The mechanism of this compound is rather unique. It covalently crosslinks the JAKs into dimers and inactivates their kinase activities. This effect on the JAKs is very specific. It does not affect many other kinases. As a consequence, it induces apoptosis of tumor cells, particularly those with constitutively activated JAK/STAT3. The JAK family kinases are important targets for anti-cancer and anti-inflammation drugs. This discovery provides a new direction for JAK inhibitor drug research and development.  It also helps to understand the mechanisms of the Traditional Chinese Medicines in treating cancer.

  

    Full text:http://cancerres.aacrjournals.org/cgi/content/full/69/18/7302

 
weimoban
About Us News Research Faculty Education&Trainning Organization Contact
Brief Introduction
History
Address from the Director
Directors
Administration
Research
Events
Int'l cooperation
Target
Discovery
Development
Translation
Academician
PI
Graduate Students
Post Graduate Students